Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Expert Opinion on Investigational Drugs|October 7, 2017
Directing the use of DDR kinase inhibitors in cancer treatmentInger Brandsma, Emmy D G Fleuren, Chris T Williamson, et al.
DNA Repair|July 23, 2013
DNA-dependent SUMO modification of PARP-1Nicola Zilio, Chris T Williamson, Sebastian Eustermann, et al.
Molecular Cancer Therapeutics|February 4, 2010
ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitorsChris T Williamson, Huong Muzik, Ali G Turhan, et al.
EMBO Molecular Medicine|March 15, 2012
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53Chris T Williamson, Eiji Kubota, Jeffrey D Hamill, et al.
Oncotarget|April 19, 2017
Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLCLars F Petersen, Alexander C Klimowicz, Shannon Otsuka, et al.
Molecular Cancer Therapeutics|June 17, 2017
Modeling Therapy Resistance in BRCA1/2-Mutant CancersAmy Dréan, Chris T Williamson, Rachel Brough, et al.
Nature Communications|December 14, 2016
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1AChris T Williamson, Rowan Miller, Helen N Pemberton, et al.
Cancer Research|October 18, 2017
ATR Is a Therapeutic Target in Synovial SarcomaSamuel E Jones, Emmy D G Fleuren, Jessica Frankum, et al.
Molecular Cancer Therapeutics|July 2, 2016
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with DasatinibRowan E Miller, Rachel Brough, Ilirjana Bajrami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B CellsElizabeth A Lemm, Beatriz Valle-Argos, Lindsay D Smith, et al.
Pageof 2